ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.

Trial Profile

ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs Lapatinib (Primary) ; Docetaxel; Paclitaxel; Trastuzumab
  • Indications Adenocarcinoma; Early breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTTO
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 05 Jun 2018 Results assessing outcome of pregnancies occurring during or following trastuzumab and/or lapatinib in NeoALTTO and ALTTO trials (n=92) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results of a secondary analysis presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Sep 2017 Results (n = 2862) presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top